Tuesday , February 21 2017

From the Editor

February, 2017

  • 21 February

    Feb. 21, 2017


    We have this great Mexican restaurant that opened a few months ago in South St. Petersburg. The food is fantastic, and the service is amazing; however, because the whole family eats lower carb, we don’t go there as often as we would like. About two months ago, my wife asked ...

    Read More »

Latest Articles

February, 2017

Test Your Knowledge

Question 873

In head-to-head trials of dipeptidyl peptidase 4 (DPP-4) inhibitors vs glucagon-like peptide 1 (GLP-1) receptor agonists, GLP-1 receptor agonists showed more favorable outcomes in all of the following areas except which one of the following?


Answer: B. Greater tolerability

GLP-1 receptor agonists showed more favorable outcomes than DPP-4 inhibitors in terms of glycemic control, weight loss, beta-cell function, and reduction of postprandial triglycerides. However, DPP-4 inhibitors offered greater tolerability because GLP-1 receptor agonists were associated with a higher incidence of mild to moderate gastrointestinal adverse events.  Nauck M. Diabetes Obes Metab. 2016;18(3):203-216.


More Articles

February, 2017